Skip to content
Study details
Enrolling now

Phase 1 Trial of SBS-147 in Healthy Adults

Sparian Biosciences, Inc
NCT IDNCT07335913ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

80

Study length

about 1.1 years

Ages

18–55

Locations

1 site in CA

What this study is about

This trial is testing the safety and how people's bodies react to SBS-147. Participants will receive either SBS-147 or a placebo, which looks like SBS-147 but has no medicine. The study involves both a single dose and multiple doses of SBS-147 over 409 days.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Placebo
  • 2.Take SBS-147

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 at ascending doses

Secondary: Plasma pharmacokinetics of SBS-1000 and SBS-147 following multiple ascending doses